Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · Real-Time Price · USD
15.24
+0.75 (5.18%)
At close: Jun 24, 2025, 4:00 PM
15.24
0.00 (0.00%)
After-hours: Jun 24, 2025, 4:37 PM EDT
5.18%
Market Cap 1.35B
Revenue (ttm) 273.53M
Net Income (ttm) -226.71M
Shares Out 88.80M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE 236.20
Dividend n/a
Ex-Dividend Date n/a
Volume 1,138,232
Open 14.70
Previous Close 14.49
Day's Range 14.36 - 15.24
52-Week Range 7.36 - 25.29
Beta 0.74
Analysts Strong Buy
Price Target 33.57 (+120.35%)
Earnings Date Jul 31, 2025

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 385
Stock Exchange NASDAQ
Ticker Symbol TVTX
Full Company Profile

Financial Performance

In 2024, Travere Therapeutics's revenue was $233.18 million, an increase of 60.55% compared to the previous year's $145.24 million. Losses were -$321.55 million, 188.6% more than in 2023.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price forecast is $33.57, which is an increase of 120.35% from the latest price.

Price Target
$33.57
(120.35% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15...

11 days ago - Business Wire

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

13 days ago - Business Wire

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the FSGS community.

14 days ago - Business Wire

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

20 days ago - Accesswire

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

21 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

21 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

22 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

23 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

25 days ago - Accesswire

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

26 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

27 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Compa...

4 weeks ago - Accesswire

Travere Therapeutics: Establishing A Position After Last Week's Selloff

Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish, with ...

5 weeks ago - Seeking Alpha

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for tra...

5 weeks ago - Business Wire

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- #Inrareforlife--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Sec...

6 weeks ago - Business Wire

Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO J...

7 weeks ago - Seeking Alpha

Travere Therapeutics Reports First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- #1Q25earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. “As the only fully approv...

7 weeks ago - Business Wire

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversio...

2 months ago - Business Wire

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

European Commission converts conditional approval of FILSPARI (sparsentan)  into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation f...

2 months ago - PRNewsWire

Travere Therapeutics to Report First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- #1Q25Earnings--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of t...

2 months ago - Business Wire